Vaccine Contract Manufacturing Market by Type (Attenuated Vaccine, DNA Vaccines, Inactivated Vaccine), Function (Downstream, Upstream), Application - Global Forecast 2024-2030

Vaccine Contract Manufacturing Market by Type (Attenuated Vaccine, DNA Vaccines, Inactivated Vaccine), Function (Downstream, Upstream), Application - Global Forecast 2024-2030

The Vaccine Contract Manufacturing Market size was estimated at USD 5.06 billion in 2023 and expected to reach USD 5.51 billion in 2024, at a CAGR 9.21% to reach USD 9.39 billion by 2030.

Vaccine contract manufacturing refers to outsourcing vaccine production processes to third-party organizations, known as contract manufacturing organizations (CMOs). These specialized companies possess the expertise, equipment, and facilities to produce vaccines at various stages, from initial development to full-scale production and packaging. Vaccine manufacturers partner with CMOs to expedite the development and manufacturing process, leverage specialized capabilities, manage costs, and ensure supply chain flexibility. The vaccine contract manufacturing market encompasses companies that provide a range of services on a contract basis for the pharmaceutical industry. This includes the production of vaccines at various stages, from early-stage development, such as preclinical trials, through to large-scale commercial production. It often involves upstream processes, such as antigen production, and downstream processes, including filling, finishing, and packaging. Vaccine contract manufacturers serve as critical partners for pharmaceutical firms, biotechnology companies, and research institutions that require additional capability or expertise in vaccine production. The vaccine contract manufacturing is growing due to increasing outbreaks of infectious diseases worldwide, growing governmental regulations and support for vaccine development, and rising vaccinations of newborns and children. However, the market faces certain challenges, such as the high cost associated with vaccines and the lack of proper storage infrastructure. On the other hand, technological advancements in mRNA vaccine technology and strategic partnerships and collaborations with governments and non-governmental organizations present potential opportunities for the vaccine contract manufacturing market.

Regional Insights

The Americas region, with countries such as the United States and Canada, is characterized by advanced healthcare systems and a high degree of health awareness among the population. The United States stands as a prominent country in vaccine research. It has a vibrant ecosystem for biotech patents, with the government, industry, and academia actively investing in new vaccine technologies. In South America, increasing investment in biotechnology, government incentives for pharmaceutical manufacturing, growing public health expenditure, and the presence of bio-manufacturing facilities support the adoption of vaccine contract manufacturing. Europe has a mature vaccine contract manufacturing industry, benefiting from high-quality manufacturing standards and a stringent regulatory landscape. European Union (EU) countries actively engage in research and innovation, with a strong network of biotech firms and research institutes. The Middle East, while historically reliant on imported vaccines, is gradually developing its vaccine manufacturing capabilities, with nations including the United Arab Emirates and Saudi Arabia investing in local production facilities. Africa's market is heavily influenced by global health initiatives and partnerships focused on providing access to vaccines for all economic backgrounds. Asia Pacific represents a dynamic and rapidly growing vaccine contract manufacturing market due to its large population base, increasing healthcare expenditures, and growing awareness of the need for immunizations. Nations such as India and China are at the forefront, with a substantial number of manufacturing facilities contributing to the global vaccine supply. China has made significant investments in biotech and vaccine innovation, emphasizing the importance of technological upgrades. Japanese companies are investing in next-generation vaccines, including mRNA and DNA-based vaccines, while the government supports research through initiatives.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Vaccine Contract Manufacturing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

• Increasing demand for vaccines leading to capacity expansion by contract manufacturers
• Key advantages such as cost and time saving offered by contract services
• Vaccination coverage across the globe

Market Restraints

• Limited outsourcing by well-established vaccine manufacturers

Market Opportunities

• Rising global demand to cater to the growing population of varied age groups
• Innovation and robust vaccine pipeline
• Favorable government insights and guidelines to speed up the vaccine manufacturing

Market Challenges

• Pharma companies manufacturing operations in-house to gain strategic control

Market Segmentation Analysis

• Type: Growing adoption of attenuated vaccines to enhance immune systems
• Function: Increasing usage of downstream processing formulations that involve the purification and formulation of the bioproducts
• Application: Rising potential of vaccine contract manufacturing for human use to protect populations against infectious diseases

Market Disruption Analysis

• Porter’s Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Vaccine Contract Manufacturing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Vaccine Contract Manufacturing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)

Vaxcyte, Inc. has reinforced its collaboration with Lonza Group AG, a contract development and manufacturing organization, to ensure the global launch preparedness of its line of pneumococcal conjugate vaccines (PCVs), namely VAX-24 and VAX-31, intended to protect both adult and pediatric demographics. In a significant deal, Vaxcyte will rely on Lonza's considerable manufacturing expertise to expedite the clinical progression of its vaccine candidates, beginning with VAX-24 in the US adult market. To meet the expected long-term worldwide demand, Lonza is dedicated to the establishment of a custom manufacturing suite at their state-of-the-art Ibex Dedicate Biopark in Visp, Switzerland, with the completion of its construction design and equipment installation slated for 2024.

Oxford Acquires ABL Europe From Institut Mérieux For EUR 15 Mn

Oxford Biomedica plc, a vaccine contract development and manufacturing organization (CDMO), has purchased ABL Europe SAS from TSGH SAS, part of the Institut Mérieux Group, for a total consideration of EUR 15 million. The deal encompasses EUR 10 million of liquid assets infused into ABL Europe by Institut Mérieux before completion. The integration of ABL Europe into Oxford Biomedica's operations is expected to catapult the latter into the vanguard of global CDMOs within the cell and gene therapy field, enhancing its service offering and increasing its production capabilities, especially in process and analytical development, as well as early-stage manufacturing.

Pfizer Inks USD 183M Contract Manufacturing Deal With Samsung Biologics

Samsung Biologics has confirmed its contract with Pfizer Inc. to manufacture COVID-19 vaccines for Moderna in a regulatory announcement, valued at 241 billion WON (USD 183 million), valid through 2029. As disclosed by the company, Samsung is directing substantial investment into the development of antibody-drug conjugates (ADCs), with manufacturing capabilities anticipated to come online within the year at their Incheon facility, fostering growth and diversification in their service offerings.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Vaccine Contract Manufacturing Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Vaccine Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc, Ajinomoto Bio-Pharma Services by Ajinomoto Co., Inc., Aton (Shanghai) Biotech Co., Ltd., Avid Bioservices, Inc., Catalent, Inc., Charles River Laboratories International, Inc., CSL Limited, Curia Global, Inc., Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Emergent BioSolutions Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation, Gedeon Richter PLC, GlaxoSmithKline PLC, ICON PLC, IDT Biologika GmbH, KBI Biopharma, Inc. by JSR Corporation, Klocke Pharma-Service GmbH, Lonza Group Ltd., Merck KGaA, Moderna, Inc., Pfizer Inc., Pharmaceutical Product Development by Thermo Fisher Scientific Inc., Recipharm AB, Serum Institute of India, and Vetter Pharma-Fertigung GmbH & Co. KG.

Market Segmentation & Coverage

This research report categorizes the Vaccine Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type

• Attenuated Vaccine
• DNA Vaccines
• Inactivated Vaccine
• Subunit Vaccines
• Toxoid Vaccines
• Function
• Downstream
• Analytical & QC studies
• Fill & Finish Operations
• Packaging
• Upstream
• Bacterial Expression Systems
• Baculovirus or Insect Expression Systems
• Mammalian Expression Systems
• Yeast Expression Systems

Application

• Human Use
• Veterinary

Region

• Americas
• Argentina
• Brazil
• Canada
• Mexico
• United States
• California
• Florida
• Illinois
• New York
• Ohio
• Pennsylvania
• Texas
• Asia-Pacific
• Australia
• China
• India
• Indonesia
• Japan
• Malaysia
• Philippines
• Singapore
• South Korea
• Taiwan
• Thailand
• Vietnam
• Europe, Middle East & Africa
• Denmark
• Egypt
• Finland
• France
• Germany
• Israel
• Italy
• Netherlands
• Nigeria
• Norway
• Poland
• Qatar
• Russia
• Saudi Arabia
• South Africa
• Spain
• Sweden
• Switzerland
• Turkey
• United Arab Emirates
• United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year